OA12125A - Ox(adi)azolyl-hydroxamic acids useful as procollagen C-proteinase inhibitors. - Google Patents

Ox(adi)azolyl-hydroxamic acids useful as procollagen C-proteinase inhibitors. Download PDF

Info

Publication number: OA12125A
Authority: OA; OAPI
Prior art keywords: compound; formula; solution; mixture; préparation
Prior art date: 1999-12-23

Application number

OA1200200192A

Other languages

English (en)

Inventor

Simon Bailey

Stephane Billotte

Andrew Michael Derrick

Paul Vincent Fish

Kim James

Nicholas Murray Thomson

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-23

Filing date

2000-12-12

Publication date

2006-05-05

2000-12-12 Application filed by Pfizer filed Critical Pfizer

2006-05-05 Publication of OA12125A publication Critical patent/OA12125A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/48—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
- C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)

OA1200200192A 1999-12-23 2000-12-12 Ox(adi)azolyl-hydroxamic acids useful as procollagen C-proteinase inhibitors. OA12125A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9930570.8A GB9930570D0 (en)	1999-12-23	1999-12-23	Therapy

Publications (1)

Publication Number	Publication Date
OA12125A true OA12125A (en)	2006-05-05

Family

ID=10866986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200192A OA12125A (en)	1999-12-23	2000-12-12	Ox(adi)azolyl-hydroxamic acids useful as procollagen C-proteinase inhibitors.

Country Status (32)

Country	Link
EP (1)	EP1240152B1 (de)
JP (1)	JP2003519133A (de)
KR (1)	KR20020067570A (de)
CN (1)	CN1423638A (de)
AP (1)	AP2002002554A0 (de)
AR (1)	AR031085A1 (de)
AT (1)	ATE284393T1 (de)
AU (1)	AU1875601A (de)
BG (1)	BG106866A (de)
BR (1)	BR0016717A (de)
CA (1)	CA2395186C (de)
CO (1)	CO5261622A1 (de)
DE (1)	DE60016629T2 (de)
EA (1)	EA200200596A1 (de)
EE (1)	EE200200358A (de)
ES (1)	ES2231292T3 (de)
GB (1)	GB9930570D0 (de)
GT (1)	GT200000221A (de)
HU (1)	HUP0204585A3 (de)
IL (1)	IL149372A0 (de)
IS (1)	IS6363A (de)
MA (1)	MA26858A1 (de)
MX (1)	MXPA02006315A (de)
NO (1)	NO20023058L (de)
OA (1)	OA12125A (de)
PA (1)	PA8508301A1 (de)
PE (1)	PE20010951A1 (de)
PL (1)	PL357512A1 (de)
SK (1)	SK8102002A3 (de)
TN (1)	TNSN00250A1 (de)
TR (1)	TR200201642T2 (de)
WO (1)	WO2001047901A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0025310D0 (en) *	2000-10-16	2000-11-29	Pfizer Ltd	Process
US6452041B1 (en)	2000-10-16	2002-09-17	Pfizer Inc.	Olefination process to itaconate and succinate derivatives
GB0031321D0 (en) *	2000-12-21	2001-02-07	Pfizer Ltd	Treatment
US6716861B2 (en)	2000-12-21	2004-04-06	Pfizer, Inc.	3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors
GB0108097D0 (en) *	2001-03-30	2001-05-23	Pfizer Ltd	Compounds
GB0108102D0 (en) *	2001-03-30	2001-05-23	Pfizer Ltd	Compounds
US6645993B2 (en)	2001-03-30	2003-11-11	Warner-Lambert Company	3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6821972B2 (en)	2001-03-30	2004-11-23	Pfizer Inc.	3-heterocyclylpropanohydroxamic acid PCP inhibitors
GB0202254D0 (en) *	2002-01-31	2002-03-20	Pfizer Ltd	Prevention of scarring
GB0204159D0 (en) *	2002-02-22	2002-04-10	British Biotech Pharm	Metalloproteinase inhibitors
US8133903B2 (en)	2003-10-21	2012-03-13	Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center	Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
EA008596B1 (ru)	2003-04-29	2007-06-29	Пфайзер Инк.	5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da)	2004-04-07	2009-03-16	Pfizer Ltd	Pyrazolo-[4,3-D]-pyrimidiner
WO2009097893A1 (en) *	2008-02-04	2009-08-13	Proyecto De Biomedicina Cima, S.L.	Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp
CN106103431B (zh)	2014-01-10	2019-03-15	葛兰素史密斯克莱知识产权（第2 号）有限公司	羟基甲酰胺衍生物及其用途
CN108530378B (zh) *	2018-05-29	2021-09-14	济南大学	一类含有噁二唑结构的氮原子双取代异羟肟酸类化合物、用途及其制备方法
CN108721282B (zh) *	2018-07-13	2022-02-15	南京市儿童医院	Uk383367在制备用于减轻肾纤维化相关病症的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997031892A1 (fr) *	1996-03-01	1997-09-04	Sankyo Company, Limited	Derives d'acide hydroxamique
DZ2741A1 (fr) *	1998-03-10	2003-09-08	Smithkline Beecham Corp	Composés nouveaux antagonistes des récepteurs de vitronectine procédé pour leur préparation et compositions.

1999
- 1999-12-23 GB GBGB9930570.8A patent/GB9930570D0/en not_active Ceased
2000
- 2000-12-07 PA PA20008508301A patent/PA8508301A1/es unknown
- 2000-12-12 TR TR2002/01642T patent/TR200201642T2/xx unknown
- 2000-12-12 ES ES00981523T patent/ES2231292T3/es not_active Expired - Lifetime
- 2000-12-12 BR BR0016717-7A patent/BR0016717A/pt not_active Application Discontinuation
- 2000-12-12 EE EEP200200358A patent/EE200200358A/xx unknown
- 2000-12-12 JP JP2001549373A patent/JP2003519133A/ja active Pending
- 2000-12-12 MX MXPA02006315A patent/MXPA02006315A/es active IP Right Grant
- 2000-12-12 WO PCT/IB2000/001855 patent/WO2001047901A1/en not_active Ceased
- 2000-12-12 AU AU18756/01A patent/AU1875601A/en not_active Abandoned
- 2000-12-12 HU HU0204585A patent/HUP0204585A3/hu unknown
- 2000-12-12 SK SK810-2002A patent/SK8102002A3/sk unknown
- 2000-12-12 DE DE60016629T patent/DE60016629T2/de not_active Expired - Fee Related
- 2000-12-12 AT AT00981523T patent/ATE284393T1/de not_active IP Right Cessation
- 2000-12-12 PL PL00357512A patent/PL357512A1/xx unknown
- 2000-12-12 KR KR1020027008179A patent/KR20020067570A/ko not_active Ceased
- 2000-12-12 AP APAP/P/2002/002554A patent/AP2002002554A0/en unknown
- 2000-12-12 EP EP00981523A patent/EP1240152B1/de not_active Expired - Lifetime
- 2000-12-12 IL IL14937200A patent/IL149372A0/xx unknown
- 2000-12-12 CA CA002395186A patent/CA2395186C/en not_active Expired - Fee Related
- 2000-12-12 EA EA200200596A patent/EA200200596A1/ru unknown
- 2000-12-12 OA OA1200200192A patent/OA12125A/en unknown
- 2000-12-12 CN CN00817410A patent/CN1423638A/zh active Pending
- 2000-12-15 CO CO00095450A patent/CO5261622A1/es unknown
- 2000-12-20 PE PE2000001370A patent/PE20010951A1/es not_active Application Discontinuation
- 2000-12-21 AR ARP000106851A patent/AR031085A1/es unknown
- 2000-12-21 GT GT200000221A patent/GT200000221A/es unknown
- 2000-12-22 TN TNTNSN00250A patent/TNSN00250A1/fr unknown
2002
- 2002-04-26 IS IS6363A patent/IS6363A/is unknown
- 2002-06-18 MA MA26694A patent/MA26858A1/fr unknown
- 2002-06-24 NO NO20023058A patent/NO20023058L/no not_active Application Discontinuation
- 2002-06-24 BG BG106866A patent/BG106866A/bg unknown

Also Published As

Publication number	Publication date
SK8102002A3 (en)	2003-09-11
CO5261622A1 (es)	2003-03-31
CA2395186A1 (en)	2001-07-05
IL149372A0 (en)	2002-11-10
MA26858A1 (fr)	2004-12-20
CN1423638A (zh)	2003-06-11
HUP0204585A2 (hu)	2003-04-28
ATE284393T1 (de)	2004-12-15
EA200200596A1 (ru)	2002-12-26
MXPA02006315A (es)	2002-11-29
PL357512A1 (en)	2004-07-26
WO2001047901A1 (en)	2001-07-05
NO20023058L (no)	2002-08-23
ES2231292T3 (es)	2005-05-16
GT200000221A (es)	2002-06-14
KR20020067570A (ko)	2002-08-22
AU1875601A (en)	2001-07-09
DE60016629T2 (de)	2005-12-08
TNSN00250A1 (fr)	2002-05-30
EP1240152A1 (de)	2002-09-18
CA2395186C (en)	2006-03-28
NO20023058D0 (no)	2002-06-24
EP1240152B1 (de)	2004-12-08
BG106866A (bg)	2003-03-31
BR0016717A (pt)	2002-09-03
PA8508301A1 (es)	2002-08-26
EE200200358A (et)	2003-10-15
GB9930570D0 (en)	2000-02-16
AP2002002554A0 (en)	2002-06-30
IS6363A (is)	2002-04-26
DE60016629D1 (de)	2005-01-13
TR200201642T2 (tr)	2002-11-21
AR031085A1 (es)	2003-09-10
HUP0204585A3 (en)	2006-01-30
JP2003519133A (ja)	2003-06-17
PE20010951A1 (es)	2001-09-24

Publication	Publication Date	Title
AU760181B2 (en)	2003-05-08	Aminobutanoic acid derivatives
US5300501A (en)	1994-04-05	Peptidyl derivatives
US5039805A (en)	1991-08-13	Novel benzoic and phenylacetic acid derivatives
US5569665A (en)	1996-10-29	Peptidyl derivatives and their use as metalloproteinases inhibitors
US5571792A (en)	1996-11-05	Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
JP2571230B2 (ja)	1997-01-16	５−アミノ−４−ヒドロキシ吉草酸誘導体の製造方法
EP1240152B1 (de)	2004-12-08	Ox(adi)azoly-hydroxamsäuren und ihre verwendung als prokollagen c-proteinase inhibitoren
US6235717B1 (en)	2001-05-22	Pharmaceutical compounds
JPH08500124A (ja)	1996-01-09	メタロプロテイナーゼインヒビターとしてのペプチジル誘導体
JPH04211095A (ja)	1992-08-03	新規ジペプチド、その製造方法及び薬剤におけるレニン阻害剤としてのその使用
WO1996023791A1 (en)	1996-08-08	Bridged indoles as matrix metalloprotease inhibitors
EP1373264B1 (de)	2004-12-22	3-heterocyclylpropanohydroxamsäure als prokollagen c-proteinase hemmer
US8957205B2 (en)	2015-02-17	Cycloalkane carboxamide derivatives and production process of same
JPH07118217A (ja)	1995-05-09	抗ウイルス活性を持つ新規擬ペプチド
US6448278B2 (en)	2002-09-10	Procollagen C-proteinase inhibitors
US5773428A (en)	1998-06-30	Matrix metalloprotease inhibitors
ES2260161T3 (es)	2006-11-01	Acidos 3-oxadiazolilpropanohidroxamicos utiles como inhibidores de proteinasa de procolageno c.
EP1373231B1 (de)	2005-06-08	3-heterocyclyl propanohydroxamsäure-derivaten als pcp inhibitoren
JPH0925293A (ja)	1997-01-28	ヒスチジル−ヒドロキサム酸誘導体
MX2008008997A (en)	2008-09-26	Cycloalkanecarboxamide derivative and method for producing same
JPH0395168A (ja)	1991-04-19	ジペプチド化合物